Lys209
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys209  -  H1D (human)

Site Information
KPKSGkPkVTkAKKA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 480275

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
liver cancer ( 2 , 3 ) , hepatocellular carcinoma ( 2 , 3 )
Relevant cell line - cell type - tissue:
HepG2 (hepatic) ( 2 , 3 ) , NCI-H3255 (pulmonary) ( 1 )

References 

1

Guo A (2006) CST Curation Set: 1208; Year: 2006; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

2

Mitchell J (2005) CST Curation Set: 867; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info